UK Life Sciences Innovation Signals Report, Q1-Q3 2026
Download the UK Life Sciences Innovation Signals Report from Frazier & Deeter, Q1-Q3 2026
Headline funding, trial performance and regulatory progress suggest positive momentum for the UK life sciences sector. Yet beneath the surface, important questions remain about how effectively innovation is being funded, developed and adopted.
This report examines three critical indicators, Capital, Capability and Conversion, to assess where momentum is building and where barriers to growth persist. From increasingly concentrated investment activity to clinical trial delivery challenges and the ongoing adoption gap, the findings provide a data-driven view of the opportunities and risks shaping the sector’s next phase of growth.
Since the January–September reporting period, two developments reinforce the signals in this report. O Mass Therapeutics announced an oversubscribed £230m ($310m) Series C, led by Bain Capital Life Sciences, Forbion and Novo Holdings. Separately, DHSC reported that the average set-up time for commercial clinical trials fell to 100 days in the three months to March 2026, with all 24 trials in that cohort set up within 150 days, exceeding the 95% target.
These developments were announced in October 2026 and are therefore not reflected in the January – September figures in this report.
Author: Asma Aslam, Head of Life Sciences & R&D Tax, Frazier & Deeter UK